Details of the Drug

General Information of Drug (ID: DMTMCPZ)

Drug Name

KB001A

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 2	[1]
Infectious disease	1A00-CA43.1	Phase 2	[2]
------------------------------------------------------------------------------------

Affected Organisms

Bacteria

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pseudomonas PcrV protein type III (Pseudo pcrV)	TTLK9NJ	O30527_PSEAI	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00638365) Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01695343) Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. U.S. National Institutes of Health.
3	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491.